Lyme disease vaccine edging closer with Valneva and Pfizer data

Franco-American pairing Valneva (Euronext: VLA) and Pfizer (NYSE: PFE) have reported new data on their Lyme disease vaccine candidate, VLA15.

The antibody persistence data is from six months after the completion of a three-dose or a two-dose vaccination schedule.

"Each new report of positive data takes us a step closer to potentially bringing this vaccine to both adults and children"As observed in previous clinical studies with VLA15, antibody levels declined over time in all study groups but remained above baseline, confirming their persistence six months after completion of both vaccination schedules.